Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | CPT1A | P50416 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22519562 | 1.00 | MEN1 (0.46) | MEN1KMT2ACPT2CPT1ANPC1 | |
| SCHEMBL13363847 | 0.76 | KMT2A (0.48) | MEN1KMT2A | |
| SCHEMBL16138577 | 0.76 | KMT2A (0.48) | MEN1KMT2A | |
| SCHEMBL8189090 | 0.76 | KMT2A (0.48) | MEN1KMT2A | |
| SCHEMBL8498367 | 0.75 | MEN1 (0.53) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8826226 | 0.75 | MEN1 (0.53) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8826219 | 0.75 | MEN1 (0.53) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8498369 | 0.75 | MEN1 (0.53) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8694016 | 0.74 | MEN1 (0.47) | MEN1KMT2A | |
| SCHEMBL9201637 | 0.73 | CHRM1 (0.42) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230018590-A1 | COMPOUNDS AND METHODS FOR REGULATING, LIMITING, OR INHIBITING AVIL EXPRESSION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230018590-A1 | COMPOUNDS AND METHODS FOR REGULATING, LIMITING, OR INHIBITING AVIL EXPRESSION | VCL, HDLBP, VHL | MEN1 584/4885KMT2A 2863/4885CPT2 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.